在肺高血压中强化利尿疗法 - - 血动力学和功能变化的回顾性评估
Adam Rafałowicz1, Jakub Mierzejewski1, Łukasz Czuba1
1Department of Cardiology, Medical University of Bialystok, Poland.
Advances in medical sciences
|October 3, 2025
概括
在肺高血压 (PH) 患有流体过载的患者中,强化利尿疗法似乎能够稳定运动能力,并防止心脏功能在六个月内恶化.
科学领域:
- 心脏病学 心脏病学
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 利尿剂对于在肺高血压 (PH) 中控制液体过载至关重要.
- 强化利尿剂治疗对PH患者血液动力学和功能参数的具体影响仍未得到充分研究.
- 这项研究调查了升级的利尿剂治疗对患者病情恶化的影响.
研究的目的:
- 分析强化利尿剂治疗对肺高血压 (PH) 患者血液动力学和功能性参数的影响.
- 评估是否增加的利尿剂剂量可以防止PH患者的PH状况恶化,患有流体过载.
主要方法:
- 对38名PH患者的回顾性分析,分为两组:第1组 (n=24,没有利尿剂变化) 和第2组 (n=14,增加利尿剂量).
- 测量包括心声学参数,6分钟步行测试距离 (6MWTd) 和脑性尿素 (NT-proBNP) 的N端前激素在基线和6个月.
主要成果:
- 2组最初呈现出较大的液体过载和心脏应变指标 (例如,更大的IVCd,RVIDd,更高的NT-proBNP).
- 在6个月的时间里,第一组的心脏尺寸和功能显著恶化 (IVCd,sPAP增加;TAPSE/sPAP比率下降).
- 第二组没有出现显著的恶化,这表明强化利尿剂治疗的稳定作用.
结论:
- 强化利尿剂疗法对PH患者的运动能力产生稳定性影响,这些患者有过多的液体负荷.
- 这种治疗方法似乎可以在6个月的随访期内防止心脏功能恶化.
相关概念视频
01:22Heart Failure Drugs: Diuretics
804
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
804
01:22Heart Failure VI: Adjunct Therapies
255
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
255
01:30Heart Failure V: Medical Management
218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
557
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
557
01:30Pulmonary Hypertension: Classification and Pathogenesis
576
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
576
01:29Heart Failure II: Pathophysiology
722
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
722